Beactica Therapeutics
Wei Berts is a highly experienced Principal Scientist with a career spanning over two decades in the pharmaceutical and biotechnology sectors. Currently serving as Principal Scientist at Beactica since May 2016, Wei has also held similar roles at OnTarget Chemistry since 2009 and at Onco Targeting AB from September 2009 to November 2015. Prior to these positions, Wei worked as a Research Chemist at Biovitrum from January 2003 to January 2009 and at Pharmacia Upjohn from January 2000 to December 2002. Wei's early career includes a role as a Research Chemist at Active Biotech from October 1999 to January 2000.
This person is not in any teams
Beactica Therapeutics
Beactica Therapeutics AB is a precision oncology company committed to the fight against cancer. The company is advancing a pipeline of novel small molecule therapeutics to treat genetically defined cancers with significant unmet clinical need. Beactica’s approach is centered around targeting disease proteins with synthetic lethality vulnerabilitiesby applying its molecular interaction-based drug discovery engine to generate novel small molecule across synergistic modalities, including allosteric modulators and targeted protein degraders (PROTACs). Beactica deliver value to patients and shareholders by advancing its programmes into early clinical trials.